Research shows hypoxia-triggered TFF3 boosts cell proliferation in hepatoblastoma, suggesting it can be a therapeutic target and biomarker.
TFF3 is a hypoxia-inducible factor that enhances HB cell proliferation, survival and chemoresistance. Its tumour-promoting activity through C-MYC and mTOR pathways identifies TFF3 as a potential therapeutic target and circulating biomarker in hepatoblastoma.
No takes yet. Share an insight, caveat, or question.
Martínez‐Pérez et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: